Secondary Progressive Multiple Sclerosis (SPMS): A Patient Guide
At a Glance
SPMS is a phase of multiple sclerosis in which physical or cognitive function gradually worsens over time, with or without relapses. Doctors use recent symptoms, relapses, and MRI findings to assess activity and tailor disease-modifying and supportive care.
Secondary Progressive Multiple Sclerosis (SPMS) represents a transition in the way the disease behaves over time. For many, MS begins with a relapsing-remitting course characterized by distinct attacks followed by periods of recovery. SPMS develops when this pattern shifts toward a more gradual and persistent accumulation of physical or cognitive challenges that occur independently of those earlier episodic relapses [1][2]. This shift is not a sudden biological switch; rather, it is a slow evolution where the underlying disease mechanisms transition from being dominated by periodic inflammation to a more continuous, overlapping process of neurodegeneration and compartmentalized inflammation [3].
Understanding your specific presentation of SPMS is critical. Clinicians primarily distinguish between “active” disease—where there is still evidence of new inflammatory activity on an MRI or through a clinical relapse over a recent period—and “non-active” disease, where such visible signs are absent [4]. This activity status is an important consideration, though not the sole determinant, in deciding whether to continue, switch, or start disease-modifying therapies (DMTs). Treatment choices also heavily depend on your age, prior medication responses, comorbidities, and personal preferences [5][6].
Activity vs. Progression: A Quick Summary
- Activity: Refers to active inflammation, identified by clinical relapses or new/enlarging spots on an MRI over a defined period.
- Progression: Refers to the gradual worsening of daily function and disability over time, independent of relapses.
- Note: You can have activity without progression, progression without activity, both, or neither. These states can change over time.
As the disease moves into this progressive phase, the focus of your medical care naturally expands. While managing inflammation remains a goal for many, equal importance is placed on a multidisciplinary approach to managing daily life [7]. This involves proactively addressing the symptoms that most impact your independence, such as mobility changes, fatigue, bladder function, and cognitive processing speed. By working with a diverse team of specialists—including physical therapists and urologists—you can focus on maintaining your function and protecting your overall quality of life [8].
Living with SPMS means navigating a more subtle, long-term relationship with your health. Because the changes are often slow, monitoring requires a steady, consistent approach to clinical testing and imaging to track your progress accurately over time [9]. With a clear understanding of your disease activity and a proactive management plan, you can take a central role in directing your care and maintaining your daily priorities [2].
In this guide
6 chapters
The Path to Secondary Progressive MS
Learn how relapsing-remitting MS can transition to secondary progressive MS, how doctors assess disability, and what treatment and monitoring may involve.
Tracking the Transition: How SPMS is Confirmed
Learn how doctors confirm secondary progressive multiple sclerosis, including EDSS, walking and cognitive tests, PIRA, and causes of temporary worsening.
Active vs. Non-Active: Categorizing Your SPMS
Learn how SPMS is classified as active or non-active and with or without progression, and what MRI, relapses, and disability changes mean for treatment.
Choosing Your Treatment: DMTs in the SPMS Phase
Learn how active versus non-active secondary progressive MS affects DMT choices, siponimod safety, medication switching, rebound risk, and rehabilitation.
Daily Life and Symptom Management in SPMS
Learn how to manage daily life with SPMS, including fatigue, mobility, spasticity, bladder care, cognitive changes, mental health, and treatment options.
Long-Term Tracking: MRI and Clinical Monitoring
Learn how secondary progressive multiple sclerosis is monitored with clinical exams, MRI, disability tests, and checks including bone, heart, and skin health.
Common questions in this guide
What is secondary progressive multiple sclerosis, and how is it different from relapsing-remitting MS?
How do clinicians recognize that someone is moving from relapsing-remitting MS to SPMS?
What does active or non-active SPMS mean?
Can SPMS worsen without a relapse or new MRI lesion?
How are treatment decisions made for people with SPMS?
Which specialists can help manage SPMS symptoms?
Get notified when new evidence is published on secondary progressive multiple sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A, Therapontos C, Horakova D, et al.
Multiple sclerosis and related disorders 2021; (50()):102778 doi:10.1016/j.msard.2021.102778.
PMID: 33592384 - 2
Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.
Adamczyk-Sowa M, Adamczyk B, Kułakowska A, et al.
Neurologia i neurochirurgia polska 2020; (54(5)):384-398 doi:10.5603/PJNNS.a2020.0082.
PMID: 33058113 - 3
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.
Lassmann H
Frontiers in immunology 2018; (9()):3116 doi:10.3389/fimmu.2018.03116.
PMID: 30687321 - 4
MRI versus relapse: optimal activity monitoring for management of progressive multiple sclerosis.
Giovannoni G, Hetherington S, Jones E, et al.
Brain communications 2025; (7(1)):fcaf010 doi:10.1093/braincomms/fcaf010.
PMID: 39906569 - 5
Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA.
Ziemssen T, Hoffmann O, Klotz L, et al.
JMIR research protocols 2020; (9(7)):e19598 doi:10.2196/19598.
PMID: 32499214 - 6
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials.
Bayas A, Christ M, Faissner S, et al.
Therapeutic advances in neurological disorders 2023; (16()):17562864221146836 doi:10.1177/17562864221146836.
PMID: 36710720 - 7
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Ziemssen T, Bhan V, Chataway J, et al.
Neurology(R) neuroimmunology & neuroinflammation 2023; (10(1)) doi:10.1212/NXI.0000000000200064.
PMID: 36414428 - 8
Progressive Multiple Sclerosis.
Willis MA, Fox RJ
Continuum (Minneapolis, Minn.) 2016; (22(3)):785-98 doi:10.1212/CON.0000000000000323.
PMID: 27261682 - 9
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Cadavid D, Cohen JA, Freedman MS, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(1)):94-105 doi:10.1177/1352458516638941.
PMID: 27003945
This SPMS guide is for informational purposes only and does not constitute medical advice. Your neurologist and rehabilitation team can interpret your disease activity and recommend care for your specific situation.